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Healthy People 2020 (HP2020) includes objectives to 
increase screening for breast, cervical, and colorectal cancer 
(1) as recommended by the U.S. Preventive Services Task 
Force (USPSTF).* Progress toward meeting these objectives 
is monitored by measuring cancer screening test use against 
national targets using data from the National Health Interview 
Survey (NHIS) (1). Analysis of 2015 NHIS data indicated 
that screening test use remains substantially below HP2020 
targets for selected cancer screening tests. Although colorectal 
cancer screening test use increased from 2000 to 2015, no 
improvements in test use were observed for breast and cervi-
cal cancer screening. Disparities exist in screening test use by 
race/ethnicity, socioeconomic status, and health care access 
indicators. Increased measures to implement evidence-based 
interventions and conduct targeted outreach are needed if the 
HP2020 targets for cancer screening are to be achieved and the 
disparities in screening test use are to be reduced.
NHIS is a cross-sectional household interview survey that 
yields data on a nationally representative sample of the civilian, 
noninstitutionalized population residing in the United States 
(2). Information is collected about the household, each per-
son in the family residing in that household, and a randomly 
selected sample adult (aged ≥18 years) and child (if present) 
from each family. This analysis includes data from the cancer 
control supplement, sample adult questionnaire, person files, 
and imputed income files. For each cancer screening test, adults 
were asked whether they had ever received the test. Those who 
answered that they had received a cancer screening test were 
then asked when the most recent screening test occurred (2). 
For this analysis, any report of testing for cancer was considered 
a screening test for the purpose of estimating proportions of 
the population up to date with breast, cervical, and colorectal 
cancer screening consistent with USPSTF recommendations 
as of 2015 (i.e., mammography within 2 years for women 
aged 50–74 years; Papanicolaou [Pap] test within 3 years for 
women without a hysterectomy aged 21–65 or Pap test with 
human papillomavirus test [HPV] within 5 years for women 
without a hysterectomy aged 30–65 years; fecal occult blood 
test within 1 year, sigmoidoscopy within 5 years and fecal occult 
blood test within 3 years, or colonoscopy within 10 years for 
respondents aged 50–75 years). Crude percentages, along with 
corresponding 95% confidence intervals, were presented by 
sociodemographic and health care–access characteristics, such 
as source of usual care. Overall percentages were age-adjusted, 
with age standardized to the 2000 U.S. standard population. 
Because the covariate associations for colorectal cancer screen-
ing use were similar by sex, results are reported for men and 
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women combined. Statistical testing for differences in screening 
test use by sociodemographic and health care–access charac-
teristics was performed using Wald F tests. For each screening 
exam, screening trends over time were examined using NHIS 
data from 2000, 2003, 2005, 2008, 2010, 2013, and 2015. To 
account for changes in cervical cancer screening recommen-
dations over time, only trends for Pap test within 3 years for 
women aged 21–65 years without hysterectomy were assessed. 
The Wald F test was used to determine whether differences 
in screening across the years occurred. All statistics presented 
are based on data weighted to account for the complex survey 
design of NHIS.
The final sample adult response rate was 55.2% (2). 
Mammography use remained stable from 2000 to 2015 
(Figure). In 2015, 71.5% of women aged 50–74 years reported 
having had a mammogram within the past 2 years, which is 
less than the HP2020 target of 81.1% (Figure) (Table 1). 
Compared with other racial/ethnic groups, mammography use 
was lowest among American Indians/Alaska Natives (AI/AN) 
(56.7%). Filipino women were the only group that met the 
HP2020 target. Use was lower among women who were for-
eign-born and in the United States for <10 years (53.7%) than 
among those who were U.S.-born (72.1%). The proportion 
of women who had a mammogram increased with increasing 
education and income levels. Mammography use was lowest for 
women who reported being uninsured (35.3%) and without 
a usual source of health care (32.9%) (Table 1).
From 2000 to 2015, the overall trend for cervical cancer 
screening (Pap test) use declined (Figure). In 2015, 83% of 
women reported being up to date with cervical cancer screen-
ing, which is below the HP2020 target of 93.0% (Figure) 
(Table 1). Cervical cancer screening use was lowest among 
Asian women (75.8%), especially Chinese (72.0%) and other 
Asian women (71.6%). Hispanics (78.6%) reported lower 
screening than did non-Hispanics (83.7%). Compared with 
all other age groups, women aged 21–30 years reported the 
lowest cervical cancer screening test use (78.3%). Women 
who were foreign-born, regardless of their duration of U.S. 
residence, had lower screening test use than U.S.-born women. 
The proportion of women reporting cervical cancer screen-
ing use increased with education and income levels. Cervical 
cancer screening use was lower among women without a usual 
source of health care (65.1%) than among women who had 
a usual source of care (85.5%). Compared with women who 
had insurance coverage, cervical cancer screening test use was 
lowest (63.8%) among uninsured women (Table 1).
From 2000 to 2015, colorectal cancer test use increased, 
but did not reach the HP2020 target of 70.5% (Figure). 
During 2015, 62.4% of men and women reported colorectal 
cancer screening test use consistent with USPSTF recom-
mendations. By racial group, colorectal cancer screening use 
was lowest among AI/ANs (48.4%) (Table 2). By ethnicity, 
Hispanics reported lower screening test use (47.4%) than 
did non-Hispanics (64.2%). Reported screening was lower 
among persons aged 50–64 years (57.9%) than among persons 
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Abbreviation: CRC = colorectal cancer.
* The U.S. Preventive Services Task Force (USPSTF) recommends mammography within 2 years for women aged 50–74 years.
† USPSTF recommends Papanicolaou (Pap) test within 3 years for women aged 21–65 years without hysterectomy, or Pap test with human papillomavirus test within 
5 years for women aged 30–65 years without hysterectomy. To account for changing screening recommendations over time for cervical cancer for women aged 
21–65 years without hysterectomy, only trends for Pap test within 3 years for women aged 21–65 years without hysterectomy were assessed; Pap test data for 2003 
are missing.
§ The USPSTF recommends three options for CRC screening: 1) fecal occult blood test within 1 year; 2) sigmoidoscopy within 5 years and fecal occult blood test within 
3 years; or 3) colonoscopy within 10 years for respondents aged 50–75 years.  
TABLE 1. Percentage of women who received recent breast and cervical cancer screenings, by selected sociodemographic characteristics and 
health care access — National Health Interview Survey, United States, 2015
Characteristic
Breast cancer Cervical cancer
Mammogram within ≤2 yrs* Pap test within ≤3 yrs or Pap + HPV within ≤5 yrs†
No. (%§) 95% CI p-value No. (%§) 95% CI p-value
Overall
Crude 6,747 (71.6) 70.1–73.0 NA 10,477 (82.8) 81.8–83.8 NA
Age-adjusted¶ 6,747 (71.5) 70.1–73.0 10,477 (83.0) 82.0–84.0
Race**
White 5,298 (71.8) 70.1–73.4 p = 0.035 7,844 (83.2) 82.0–84.3 p<0.001
Black 1,015 (74.3) 70.3–78.0 1,664 (85.3) 82.9–87.3
American Indian/Alaska Native 86 (56.7) 43.0–69.4 171 (76.9) 66.9–84.6
Asian 311 (66.1) 59.1–72.4 690 (75.8) 71.4–79.7
Chinese 55 (72.3) 55.4–84.6 151 (72.0) 63.8–79.0
Filipino 88 (81.5) 67.5–90.4 169 (88.9) 81.4–93.7
Other Asian 168 (57.4) 48.0–66.3 370 (71.6) 65.5–77.0
Ethnicity††
Non-Hispanic 5,906 (71.5) 69.9–73.1 p = 0.791 8,375 (83.7) 82.6–84.8 p<0.001
Hispanic 841 (72.1) 67.8–76.0 2,102 (78.6) 76.2–80.8
Puerto Rican 118 (78.1) 66.5–86.5 222 (79.5) 70.1–86.6
Mexican 272 (66.2) 59.3–72.5 864 (77.0) 73.0–80.6
Mexican-American 163 (77.2) 67.4–84.8 417 (79.0) 72.8–84.1
Central/South American 144 (74.6) 64.6–82.6 359 (80.6) 74.5–85.5
Other Hispanic 118 (78.1) 66.5–86.5 240 (80.5) 72.1–86.8
See table footnotes on next page.
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aged 65–75 years (71.8%). Foreign-born persons reported 
lower use of colorectal cancer screening (52.3% [U.S. resi-
dence ≥10 years], 36.3% [U.S. residence <10 years]) than did 
U.S.-born persons (64.6%). As education and income levels 
increased, the proportion of persons who received colorectal 
cancer screening increased. Lowest colorectal cancer screening 
use was reported by persons without a usual source of health 
care (26.3%) and persons who were uninsured (25.1%).
Discussion
Cancer screening in the United States remains below 
HP2020 targets. A previous study of cancer screening using 
data from the 2013 NHIS found that overall use of screening 
tests was below HP2020 targets, with no improvements from 
2010 to 2013 for breast, cervical, or colorectal cancer (3). 
Based on these more recent data, the overall trend from 2000 to 
2015 demonstrates that colorectal cancer screening increased, 
breast cancer screening was stable, and cervical cancer screening 
declined slightly. Few subgroups met HP2020 targets in 2015, 
with many groups remaining far below targets, and disparities 
in use of cancer screening tests exist based on race, ethnicity, 
income, and education.
The progress in increasing use of colorectal cancer screening 
is promising, but more needs to be done if the HP2020 target 
TABLE 1. (Continued) Percentage of women who received recent breast and cervical cancer screenings, by selected sociodemographic char-
acteristics and health care access — National Health Interview Survey, United States, 2015
Characteristic
Breast cancer Cervical cancer
Mammogram within ≤2 yrs* Pap test within ≤3 yrs or Pap + HPV within ≤5 yrs†
No. (%§) 95% CI p-value No. (%§) 95% CI p-value
Age group (yrs)
21–30 —§§ —§§ p = 0.556 2,594 (78.3) 75.9–80.5 p<0.001
31–40 —§§ —§§ 2,647 (87.2) 85.4–88.9
41–50 —§§ —§§ 2,180 (84.6) 82.5–86.5
51–65 —§§ —§§ 3,056 (82.0) 80.2–83.7
50–64 4,312 (71.3) 69.4–73.1 —§§ —§§
65–74 2,435 (72.2) 69.7–74.5 —§§ —§§
Sexual orientation
Gay 94 (77.2) 65.0–86.1 p = 0.380 177 (74.6) 64.9–82.4 p = 0.006
Straight 6,509 (71.8) 70.3–73.2 10,000 (83.3) 82.2–84.2
Bisexual 26 (38.3)¶¶ 14.5–69.5¶¶ 161 (77.9) 68.5–85.1
Period of U.S. residence
U.S.-born 5,692 (72.1) 70.5–73.6 p = 0.034 8,232 (84.5) 83.3–85.5 p<0.001
In U.S. <10 yrs 74 (53.7) 40.2–66.8 467 (67.3) 62.2–72.0
In U.S. ≥10 yrs 971 (70.0) 65.9–73.8 1,760 (79.3) 76.7–81.6
Education
Less than high school 867 (60.3) 55.7–64.7 p<0.001 1,215 (71.2) 67.6–74.5 p<0.001
High school graduate/GED 1,698 (68.3) 65.3–71.2 2,130 (76.4) 73.8–78.9
Some college/Associate degree 2,187 (71.0) 68.2–73.8 3,436 (83.1) 81.1–84.9
College graduate 1,970 (78.9) 76.4–81.2 3,670 (89.5) 88.1–90.7
Percentage of federal poverty threshold
<139 1,571 (58.7) 55.0–62.3 p<0.001 2,960 (75.2) 72.9–77.4 p<0.001
139–250 1,323 (63.4) 59.3–67.4 2,075 (78.2) 75.5–80.7
251–400 1,311 (73.8) 70.5–76.9 1,960 (82.3) 79.9–84.4
>400 2,542 (78.8) 76.6–80.9 3,481 (89.7) 88.2–90.9
Usual source of health care
None or hospital emergency department 393 (32.9) 26.9–39.6 p<0.001 1,406 (65.1) 61.5–68.6 p<0.001
Has usual source 6,352 (73.8) 72.3–75.3 9,069 (85.5) 84.5–86.5
Health care coverage
Private 4,186 (76.7) 74.9–78.5 p<0.001 6,739 (86.8) 85.7–87.8 p<0.001
Military 222 (74.5) 66.1–81.3 263 (92.9) 88.2–95.8
Public only 1,951 (64.3) 61.4–67.1 2,118 (78.4) 75.9–80.7
Uninsured 370 (35.3) 29.2–41.9 1,318 (63.8) 60.3–67.2
Abbreviations: CI = confidence interval; GED = General Educational Development certificate; HPV = human papillomavirus; NA = not applicable; Pap = Papanicolaou.
 * Among women aged 50–74 years.
 † Pap test for women without hysterectomy either within 3 years for women aged 21–65, or Pap with HPV test within 5 years for women aged 30–65 years.
 § Weighted percentages. Overall percentages presented as crude and age-adjusted estimates; other percentages are crude estimates.
 ¶ Age-standardized to the 2000 U.S. standard population.
 ** p-value testing for differences across four primary race groups.
 †† p-value testing for differences between Hispanic and non-Hispanics.
 §§ Not estimated for these age groups.
 ¶¶ Relative standard error >30%.  
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is to be achieved. The lack of progress for breast and cervical 
cancer screening use highlights the need for more initiatives 
to reach persons facing barriers to screening. Persons without 
a usual source of health care and the uninsured had the lowest 
test use, with the overwhelming majority of the uninsured 
not up to date with breast and colorectal cancer screening. 
The Affordable Care Act has helped to reduce such barriers 
by expanding insurance coverage and eliminating cost shar-
ing, in most insurance plans, for preventive services such as 
breast, cervical, and colorectal cancer screening rated A and B 
by the USPSTF.† Further, CDC’s Colorectal Cancer Control 
Program helps states and tribes increase colorectal cancer 
screening use by reducing some barriers and promoting the 
use of evidence-based interventions to increase screening (4). 
The National Breast and Cervical Cancer Early Detection 
Program§ provides free or low-cost screening to medically 
underserved women.
Mammography use among AI/AN declined from 73.4% in 
2013 (3) to 56.7% 2015. From 1990 to 2009, breast cancer 
TABLE 2. Percentage of adults who received recent colorectal cancer 
screenings,* by selected sociodemographic characteristics and health 
care access — National Health Interview Survey, United States, 2015
Characteristic No. (%†) 95% CI
Overall
Crude 12,650 (62.4) 61.1–63.7
Age–adjusted§ 12,650 (62.4) 61.1–63.8
Race¶,**
White 10,051 (63.7) 62.2–65.2
Black 1,777 (59.3) 56.0–62.5
American Indian/Alaska Native 160 (48.4) 38.3–58.7
Asian 595 (52.1) 46.7–57.4
Chinese 111 (56.0) 44.5–67.0
Filipino 161 (54.7) 43.2–65.7
Other Asian 323 (49.7) 43.4–56.0
Ethnicity¶,††
Non-Hispanic 11,163 (64.2) 62.7–65.6
Hispanic 1,487 (47.4) 44.1–50.8
Puerto Rican 192 (63.2) 54.3–71.2
Mexican 501 (36.0) 31.0–41.4
Mexican-American 307 (49.8) 41.9–57.8
Central/South American 240 (52.6) 43.2–61.8
Other Hispanic 247 (51.6) 43.8–59.4
Age group (yrs)¶
50–64 7,947 (57.9) 56.2–59.6
65–75 4,703 (71.8) 70.0–73.6
Sexual Orientation§§
Gay 210 (69.3) 60.6–76.8
Straight 12,195 (62.5) 61.1–63.8
Bisexual 49 (59.3) 36.6–78.6
Period of U.S. residence¶
U.S.-born 10,716 (64.6) 63.1–66.0
In U.S. <10 yrs 133 (36.3) 26.6–47.3
In U.S. ≥10 yrs 1,781 (52.3) 49.3–55.2
Education¶
Less than high school 1,681 (46.7) 43.5–50.0
High school graduate/GED 3,275 (58.2) 55.9–60.6
Some college/Associate degree 3,896 (63.5) 61.2–65.6
College graduate 3,754 (70.7) 68.7–72.7
Percentage of federal poverty threshold¶
<139 2,702 (46.9) 44.4–49.5
139–250 2,432 (56.1) 52.9–59.1
251–400 2,455 (62.6) 59.6–65.5
>400 5,060 (70.0) 68.2–71.8
Usual source of health care¶
None or hospital emergency department 997 (26.3) 22.5–30.4
Has usual source 11,651 (65.2) 63.8–66.6
Health care coverage¶
Private 7,628 (65.6) 63.9–67.2
Military 702 (77.6) 72.8–81.7
Public only 3,494 (60.1) 57.9–62.2
Uninsured 790 (25.1) 20.9–29.9
Abbreviations: CI = confidence interval; GED = General Educational 
Development certificate.
 * Includes fecal occult blood test within 1 year, sigmoidoscopy within 5 years 
and fecal occult blood test within 3 years, or colonoscopy within 10 years for 
persons aged 50–75 years.
 † Weighted percentages. Overall percentages presented as crude and age–
adjusted estimates; other percentages are crude estimates.
 § Age-standardized to the 2000 U.S. standard population.
 ¶ p<0.001.
 ** p-value testing for differences across four primary race groups.
 †† p-value testing for differences between Hispanic and non-Hispanics.
 §§ p = 0.038.  
Summary
What is already known about this topic?
Screening can lead to early detection of breast, cervical and 
colorectal cancer, when cancers might respond better to 
treatment, thereby reducing deaths. Healthy People 2020 
(HP2020) set targets for screening based on recommendations 
from the U.S. Preventive Services Task Force. Screening dispari-
ties exist for some groups defined by sociodemographics and 
access to health care.
What is added by this report?
Since 2013, some progress toward meeting the HP2020 
objective for colorectal cancer screening has occurred, but the 
trend for breast cancer screening has been static, and cervical 
cancer screening is declining. Disparities in screening persisted 
by race, ethnicity, education, and income. The uninsured and 
persons without a usual source of care had screening use far 
below the HP2020 targets.
What are the implications for public health practice?
Progress toward achieving the HP2020 targets will require 
implementation of evidence-based interventions to increase 
cancer screening.  Such interventions can be both provider- and 
patient-oriented. Screening among some racial and ethnic 
minorities and medically underserved populations is subopti-
mal and innovative approaches to eliminate these disparities 
might be needed.
† U.S. Preventive Services Task Force (USPSTF) A and B grades are defined as 
follows: A, USPSTF recommends the service and there is high certainty that 
the net benefit is substantial; B, USPSTF recommends the service and there is 
high certainty that the net benefit is moderate, or there is moderate certainty 
that the net benefit  i s  moderate to substantial .  https://www.
uspreventiveservicestaskforce.org/Page/Name/grade-definitions.
§ https://www.cdc.gov/cancer/nbccedp.
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death rates declined for white women, but increased slightly 
among AI/AN women (5). Reasons for this decline are unclear 
and warrant further investigation. However, data from this 
analysis indicate that factors associated with lower mammog-
raphy use include poverty and lack of insurance coverage or a 
usual source of health care. In addition, because of the small 
sample size and unstable estimates for AI/AN women, error 
cannot be ruled out as a potential explanation for this pattern. 
Lower mammography use might lead to breast cancer diagnosis 
at later stages and contribute to racial disparities in mortality. 
The National Breast and Cervical Cancer Early Detection 
Program supports 11 AI/AN tribes and tribal organizations to 
increase screening use in these communities (4,6).
The findings in this report are subject to at least five limita-
tions. First, the screening questions did not distinguish whether 
the test was performed for screening or diagnostic purposes; 
however, a person might be considered effectively screened in 
either instance. Second, data were self-reported and were not 
verified by medical records. Third, the overall response rate was 
55.2%, and nonresponse bias is possible, despite adjustments 
for nonresponse. Fourth, sample sizes were small and not age-
adjusted for some subgroups. Comparisons of subgroup rates 
to national targets should be interpreted with caution because 
targets were based on improvement from the 2008 baseline 
values for the national age-adjusted rate. In addition, consid-
eration should be given to the fact that targets were designed 
to be met by 2020, not 2015. Finally, screening recommenda-
tions and questions have changed over time. In 2012, screening 
every 5 years with Pap and HPV tests was added as an option 
for women aged 30–65 years. It is unclear whether this change 
might have extended screening intervals for women and thus 
contributed to the slight decline in cervical cancer screening. 
Attempts were made to account methodologically for changes 
in recommendations and questions by using consistent defini-
tions across years. Because hysterectomy status was unknown 
for 2003, Pap test data for that year were excluded Screening 
measures for the trend analysis were defined according to the 
2000 method, which makes assumptions for cases with only 
partial timing data (i.e. respondent did not provide enough 
timing detail to determine if the test came within the recom-
mended time interval). This source of bias results in slightly 
higher estimates but allows for fair comparisons over time. 
Accordingly, percentages for 2015 in the trend analysis differ 
slightly from those reported in the tables.
These findings might inform future activities to increase the 
use of screening tests as recommended. Some progress has been 
achieved toward meeting the HP2020 objective for colorectal 
cancer screening, but the trend for mammography use has 
remained static, and cervical cancer screening is declining. 
Substantial disparities persist for some subgroups, including 
persons without health insurance or a usual source of health 
care. The National Breast and Cervical Cancer Early Detection 
Program can provide access to timely breast and cervical cancer 
screening and diagnostic services for low-income, uninsured, 
and medically underserved women. For persons with access 
to health care, evidence-based interventions, such as provider 
and patient reminders about screening, can increase cancer 
screening rates (7). Innovative approaches are needed to reach 
some racial and ethnic minorities and medically underserved 
populations to improve the use of cancer screening test use 
toward the HP2020 targets.
 1Division of Cancer Prevention and Control, CDC; 2Division of Cancer 
Control and Population Sciences, National Cancer Institute, National Institutes 
of Health, Bethesda, Maryland.
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